Ver­tex founder Joshua Boger on sur­viv­ing down­turns, 'painful' part­ner­ships, and the im­por­tance of cul­ture: #JPM24

While the JP Mor­gan Health­care Con­fer­ence was full of voic­es of mea­sured op­ti­mism, root­ing for the mar­ket to bounce back in 2024, one long­time biotech leader warned against set­ting any firm ex­pec­ta­tions.

In­stead of pre­dict­ing when the down­turn may end, Ver­tex Phar­ma­ceu­ti­cals founder Joshua Boger said he ad­vis­es biotech lead­ers to ex­pect — and plan for — volatil­i­ty. Speak­ing Tues­day on an End­points News pan­el along­side Or­biMed’s Carl Gor­don and Ap­pia Bio CEO JJ Kang, Boger shared lessons learned on sur­viv­ing down­turns, strik­ing phar­ma deals, and the im­por­tance of keep­ing a com­pa­ny’s cul­ture based on his two decades of found­ing and lead­ing Ver­tex as CEO from 1989 to 2009. The 72-year-old is now serv­ing as ex­ec­u­tive chair­man of Alkeus Phar­ma­ceu­ti­cals, a start­up de­vel­op­ing a rare dis­ease drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER